The American Liver Foundation partnered with Helio Genomics to bring LiverTrace — a convenient at-home blood test for early liver cancer detection — to millions of at-risk Americans.
The American Liver Foundation (ALF) announced a new partnership with Helio Genomics that empowers millions of Americans to find out if they are at risk for, or already have, liver cancer — a rapidly growing public health crisis often called a “silent killer” because most people are unaware they have it, particularly in early stages when there are no symptoms. To launch the partnership, ALF encourages everyone to take its quick online risk quiz. For those at risk, the new LiverTrace test can provide fast, convenient liver cancer results in the privacy of home.
“Our partnership with Helio Genomics is built on a shared commitment to enhance awareness of liver cancer, improve treatment outcomes, and offer patients the peace of mind that comes with understanding their liver cancer status as early as possible. Liver cancer rates have tripled since 1980, and death rates doubled during the same time. Our goal is to provide advanced tools so that we have an educated, informed public which understands their liver cancer status before it’s too late.”
“At Helio Genomics, we’re passionately committed to transforming early cancer detection with innovative AI and easy at-home testing, empowering people to take charge of their health and prevent needless tragedy. Our partnership with the American Liver Foundation sparks real hope, allowing individuals to detect liver cancer risks from the comfort of their home. Early detection isn’t only about science—it’s about survival.”
Getting started is easy and private: Helio’s LiverTrace Collection Kit includes a visit from a certified mobile phlebotomist right to your doorstep, who collects a simple blood sample and sends it to a CLIA-certified lab for analysis. In 10 to 14 days, individuals receive confidential results through a secure, HIPAA-compliant online patient portal — empowering them to act swiftly with their doctor if needed.
Early awareness is the best defense, especially for those with risk factors such as a family history of cancer, liver cirrhosis, chronic hepatitis (HCV or HBV), alcohol-associated liver disease, obesity, type 2 diabetes, heavy alcohol and drug use, and fatty liver disease (MASLD or MASH). For more information about LiverTrace, visit livertrace.com.
About the American Liver Foundation
The American Liver Foundation (ALF) is a national community of patients, caregivers and medical professionals dedicated to helping people improve their liver health. ALF is the largest organization focused on all liver diseases and the trusted voice for patients and families living with liver disease. For more information visit liverfoundation.org or call 1-800-GO-LIVER (800-465-4837).
About Helio Genomics
Helio Genomics is a commercial stage, AI-driven techbio company specializing in diagnostics technology to pioneer cancer early detection and minimal residual disease monitoring. Its advanced blood-based multi-analyte platform uses machine learning and deep learning to detect cancer biomarkers with unprecedented accuracy, empowering clinicians and patients to act swiftly in the fight against liver cancer. Clinically validated in studies with thousands of patients, Helio Genomics is supported by an expanding commercial presence.
Source: American Liver Foundation. Read the full announcement.